Covid vaccine tracker: when will a coronavirus vaccine be ready? | World news

Pre-clinical

vaccines not yet in human trials

139

Phase 1

vaccines in small-scale safety trials

25

Phase 2

vaccines in expanded safety trials

15

Phase 3

vaccines in large-scale efficacy trials

7

Approved

vaccines approved for general use

0

Source: WHO. Last updated 25 Aug

Researchers around the world are racing to develop a vaccine against Covid-19, with more than 170 candidate vaccines now tracked by the World Health Organization (WHO).

Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months.

Vaccines mimic the virus – or part of the virus – they protect against, stimulating the immune system to develop antibodies. They must follow higher safety standards than other drugs because they are given to millions of healthy people.

Recent vaccine news

AstraZeneca has started trials for a drug which could work as a preventative option for healthy people or slow the disease’s progression in those who are already infected.
Russian health authorities have approved a coronavirus vaccine which has yet to complete clinical trials.

How are vaccines tested?

In the pre-clinical stage of testing, researchers give the vaccine to animals to see if it triggers an immune response.

In phase 1 of clinical testing, the vaccine is given to a small group of people to determine whether it is safe and to learn more about the immune response it provokes.

In phase 2, the vaccine is given to hundreds of people so scientists can learn more about its safety and correct dosage.

In phase 3, the vaccine is given to thousands of people to confirm its safety – including rare side effects – and effectiveness. These trials involve a control group which is given a placebo.

Vaccines in clinical trials

Phase in progress

Phase completed

University of Oxford/AstraZeneca

The University of Oxford vaccine is delivered via a chimpanzee virus, called the vaccine vector. The vector contains the genetic code of the protein spikes found on the coronavirus and triggers a strong immune response in the human body. The vaccine is in a combined phase 2/3 trial in the UK and
has recently gone into phase 3 trials in South Africa and Brazil.

BioNTech/Fosun Pharma/Pfizer

Wuhan Institute of Biological Products/Sinopharm

American biotech company Moderna is developing a vaccine candidate using messenger RNA (or mRNA for short) to trick the body into producing viral proteins itself. No mRNA vaccine has ever been approved for an infectious disease, and Moderna
has never brought a product to market. But proponents of the vaccine say it could be easier to mass produce than traditional vaccines.

Chinese company Sinovac is developing a vaccine based on inactivated Covid-19 particles. The vaccine has shown a promising safety profile in the early stages of testing and is now moving into Phase 3 trials in Brazil.

Beijing Institute of Biological Products/Sinopharm

CanSino Biologics Inc./Beijing Institute of Biotechnology

Kentucky Bioprocessing, Inc

Cadila Healthcare Limited

Osaka University/ AnGes/ Takara Bio

Inovio Pharmaceuticals/ International Vaccine Institute

Janssen Pharmaceutical Companies

Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences

Institute of Medical Biology, Chinese Academy of Medical Sciences

University of Queensland/CSL/Seqirus

People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.

Institute Pasteur/Themis/Univ. of Pittsburgh CVR/Merck Sharp & Dohme

Instituto Finlay de Vacunas, Cuba

Medigen Vaccine Biologics Corporation/NIAID/Dynavax

Clover Biopharmaceuticals Inc./GSK/Dynavax

ReiThera/LEUKOCARE/Univercells

Gamaleya Research Institute

University of Melbourne/Murdoch Children’s Research Institute

The Murdoch Children’s Research Institute in Australia is conducting a phase 3 trial using a nearly 100-year-old tuberculosis vaccine. The vaccine is not thought to protect directly against Covid-19 but might boost the body’s non-specific immune response.

Source: WHO. Last updated 25 Aug

Source: The Guardian

Leave a Comment

Your email address will not be published. Required fields are marked *